scholarly journals Unilateral and bilateral repetitive transcranial magnetic stimulation for treatment‐resistant late‐life depression

2019 ◽  
Vol 34 (6) ◽  
pp. 822-827 ◽  
Author(s):  
Alisson Paulino Trevizol ◽  
Kyle W. Goldberger ◽  
Benoit H. Mulsant ◽  
Tarek K. Rajji ◽  
Jonathan Downar ◽  
...  
Keyword(s):  
Transcranial Magnetic Stimulation ◽  
Magnetic Stimulation ◽  
Repetitive Transcranial Magnetic Stimulation ◽  
Late Life ◽  
Late Life Depression ◽  
Treatment Resistant

858. Efficacy of Deep Transcranial Magnetic Stimulation for Treatment Resistant Late-Life Depression

2017 ◽  
Vol 81 (10) ◽  
pp. S347 ◽  
Author(s):  
Daniel Blumberger ◽  
Yoshihiro Noda ◽  
Yuliya Knyahnytska ◽  
Jonathan Downar ◽  
Tarek Rajji ◽  
...  
Keyword(s):  
Transcranial Magnetic Stimulation ◽  
Magnetic Stimulation ◽  
Late Life ◽  
Late Life Depression ◽  
Treatment Resistant

scholarly journals Repetitive transcranial magnetic stimulation in patients with late life depression influences phenylalanine metabolism

Pteridines ◽  
2018 ◽  
Vol 29 (1) ◽  
pp. 87-90
Author(s):  
F Leblhuber ◽  
K Steiner ◽  
Jm Gostner ◽  
D Fuchs
Keyword(s):  
Transcranial Magnetic Stimulation ◽  
Magnetic Stimulation ◽  
Phenylalanine Hydroxylase ◽  
Repetitive Transcranial Magnetic Stimulation ◽  
Neuropsychiatric Symptoms ◽  
Late Life ◽  
Additional Treatment ◽  
Symptom Improvement ◽  
Therapeutic Effects ◽  
Late Life Depression

AbstractRepetitive transcranial magnetic stimulation (rTMS) is used to treat different neuropsychiatric conditions like Parkinson’s disease, essential tremor, stroke, cognitive decline, dementia and depression. rTMS may exert its therapeutic effects by influencing the biochemistry of neurotransmitters. In this exploratory study, safety symptom improvement and changes in the availability of neurotransmitter precursor amino acids were studied following prefrontal cortex (PFC) stimulation using repetitive transcranial stimulation with TheraCell apparatus R (Guth Meditec, Salach, Germany) as an additional treatment in ten patients with late life depression. Treatment was well tolerated with no serious adverse effects being observed. rTMS induced a significant improvement in the symptoms of depression and a significant decrease in the HAMD-7 (p <0.03). At the same time, the serum phenylalanine to tyrosine ratio declined significantly (p <0.04). No significant influence of rTMS on tryptophan breakdown and serum neopterin concentrations was observed. These preliminary findings indicate that rTMS may influence the activity of the enzyme phenylalanine hydroxylase (PAH) which plays a key role in the biosynthesis of neurotransmitter precursors related to neuropsychiatric symptoms in late life depression. However, results were obtained from only 10 patients. Larger studies are therefore required to support these conclusions

scholarly journals Long-Term Efficacy of Combination Therapy of Transcranial Magnetic Stimulation with Ketamine for Patients with Treatment-Resistant Depression

CNS Spectrums ◽  
2021 ◽  
Vol 26 (2) ◽  
pp. 171-171
Author(s):  
Steve Best ◽  
Dan G. Pavel ◽  
Natalie Haustrup
Keyword(s):  
Transcranial Magnetic Stimulation ◽  
Magnetic Stimulation ◽  
Repetitive Transcranial Magnetic Stimulation ◽  
Nmda Receptor Antagonist ◽  
Primary Diagnosis ◽  
Treatment Resistant Depression ◽  
Treatment Resistant ◽  
Invasive Treatment ◽  
Novel Approach ◽  
Resistant Depression

AbstractBackgroundRepetitive transcranial magnetic stimulation (rTMS) is a safe, effective and non-invasive treatment for many psychiatric illnesses, including treatment-resistant depression (TRD). Ketamine, an NMDA receptor antagonist, is also an effective antidepressant. This retrospective review examined the clinical benefits of combining these two established treatments for patients suffering from TRD in a novel approach coined combination TMS with ketamine (CTK).MethodsA group of 28 adult patients with a primary diagnosis of unipolar (n=18) or bipolar (n=10) depression received three CTK treatments a week at a private neuropsychiatric practice. Patients were given a concurrent treatment of rTMS (1Hz; 40 minutes; 130% of motor threshold) with bio-marker-determined IV ketamine infusions (0.2–4.7 mg/kg; 30 minutes). The TMS coil was positioned on the mid-prefrontal area. Frequency of treatment was dependent on patient responsiveness (10–30 sessions), which was measured as symptom reduction on the Clinical Global Impression (CGI) scale. CGI data was evaluated pre-treatment, post-treatment and at two-year follow-up.ResultsMean reduction in CGI severity for the patient group following CTK was 4.46 ± 0.54 at a 99% confidence interval and was deemed statistically significant using a paired t-test (a=0.01, t=22.81, p < 0.0001). This significant reduction in CGI severity was sustained for at least 2 years following treatment completion.ConclusionsDespite years of unsuccessful treatments, all 28 patients in this trial obtained substantial and enduring reductions in their depressive symptoms following CTK therapy. Further research into method optimization and randomized controlled trials are warranted.

Repetitive Transcranial Magnetic Stimulation Improves Depersonalization: A Case Report

CNS Spectrums ◽  
2004 ◽  
Vol 9 (5) ◽  
pp. 375-376 ◽  
Author(s):  
Alejandro M. Jiménez-Genchi
Keyword(s):  
Prefrontal Cortex ◽  
Case Report ◽  
Transcranial Magnetic Stimulation ◽  
Magnetic Stimulation ◽  
Dorsolateral Prefrontal Cortex ◽  
Repetitive Transcranial Magnetic Stimulation ◽  
Treatment Resistant ◽  
Depersonalization Disorder ◽  
Dorsolateral Prefrontal

AbstractDepersonalization disorder is a poorly understood and treatment-resistant condition. This report describes a patient with depersonalization disorder who underwent six sessions of repetitive transcranial magnetic stimulation on the left dorsolateral prefrontal cortex. Repetitive transcranial magnetic stimulation produced a 28% reduction on depersonalization scores.

Sign in / Sign up

Export Citation Format

Share Document